Drug-induced gene expression profiles that invert disease profiles have recently been illustrated to be a starting point for drug-repositioning. In this study, we validate this approach and focus on prediction of novel drugs for colorectal cancer (CRC), for which there is a pressing need to find novel anti-metastatic compounds. We computationally predicted three novel and still unknown compounds against CRC; citalopram (an anti-depressant), troglitazone (an antidiabetic) and enilconazole (a fungicide). We verified the compounds by in vitro assays of clonogenic survival, proliferation and migration and in a subcutaneous mouse model. We found evidence that the mode-of-action of these compounds may be through inhibition of TGF-β signaling. Furthermore, one compound, citalopram, reduced tumor size as well as the number of circulating tumor cells and metastases in an orthotopic mouse model of CRC. This study proposes citalopram as a potential therapeutic option for CRC patients illustrating the potential of systems pharmacology.
INTRODUCTION
Rational drug discovery has gained momentum by the recently increased availability of largescale datasets on biological activities of small molecules. Integration and utilization of these heterogeneous resources requires computational tools, as well as expert knowledge to guide the drug discovery or repositioning process. To enable the latter, a pioneering systems pharmacology study built the Connectivity Map (CMap), a collection of genome-wide gene expression readouts of cell-lines treated with more than 1,000 drug-like chemicals [1] . This approach is fundamentally based on the observation that, in many cases, drugs with similar mechanism of action in vivo also elicit similar expression responses in this in vitro model system, thus providing a starting point for drug repositioning based on expression profile similarity [1, 2] . Moreover, it was proposed that a drug-induced gene expression profile that (partially) inverts a disease-associated expression profile could hint at a potential treatment for the respective disease and indeed, by applying this concept, novel compounds have been recently proposed for inflammatory bowel disease, non-small cell lung cancer and muscle atrophy [3] [4] [5] [6] . Thus, the repositioning of drugs based on specifically tailored gene signatures has been demonstrated for these diseases. However, although an enrichment of drug-disease relations has been found among anti-correlated profiles when all diseases are considered together, it remains to be investigated how well this approach works for each individual disease where an expression profile is available.
A systematic analysis requires addressing various biases that are inherent to the CMap data, such as batch effects which can be partially removed with a normalization procedure [7] .
Furthermore, to predict new treatment candidates for a disease, the disease itself needs to be clearly defined and characterized at the molecular level. Finally, a robust gene expression profile, associated with the disease that is also relevant for the disease etiology is necessary to make accurate predictions.
Here we present a global, unbiased approach for using drug-induced gene-expression profiles to retrieve novel candidate drugs with many cancer profiles being inversely matched. Our analysis shows a particularly strong signal for colorectal cancer (CRC) which is the third most common cancer in western countries [8] . CRC patients with non-metastatic disease have excellent longterm survival as in most cases localized primary tumors can be surgically removed. However, survival rates drop significantly with the occurrence of distant metastases. Although hepatic metastases can be surgically removed in a curative intention, thereby providing long-term cure in a significant number of patients, metastatic disease often recurs, and patients succumb to recurrent metastatic disease or primarily unresectable multifocal metastases [9, 10] . The fate of CRC patients is therefore closely linked to the occurrence of distant metastases. Although the clinical significance of metastasis in CRC is evident, the process of metastasis is still poorly understood [11] . It is widely accepted that circulating tumor cells play a pivotal role in distant tumor dissemination and their detection is closely linked to the prognosis of CRC patients [12] [13] [14] [15] [16] . To actively leave the tumor, enter the blood stream, attach to the vessel endothelium in the target organ, invade, proliferate and form new lesions, abilities far beyond those of a bulk tumor cells (e.g., migration and invasion capacities) are essential for metastatic tumor cells. In that respect, to reduce the risk of (further) tumor cell dissemination in CRC patients, especially in the neoadjuvant situation (e.g., in locally advanced rectal cancer requiring neoadjuvant treatment or the "liver first" approach in synchronously metastasized CRC [17] ), there is a huge clinical need for (novel) anti-metastatic drugs.
We illustrate the power of our approach by experimentally validating three predicted novel drugs that could be repositioned for CRC. We specifically test the three predicted drugs for their potential to inhibit metastasis. We confirm in vitro that these drugs inhibit cell migration.
Secondly, we validate that they inhibit tumor growth in vivo in a subcutaneous mouse model.
Finally, using an orthotopic mouse model of CRC, we confirm the anti-metastatic properties of citalopram in vivo. Taken together, from a broad and comprehensive bioinformatics approach, via various computational and experimental filtering and validation procedures, we arrived at a very specific, clinical relevant indication in the context of CRC and propose that the antidepressant drug citalopram can serve at least as a lead for treatment of metastatic CRC.
MATERIALS AND METHODS

Connectivity Map Data
The Connectivity Map (CMap, build 02) is a large-scale microarray resource cataloguing transcriptomic responses of four human cell lines (promyelocytic leukemia HL60, breast adenocarcinoma MCF7, prostate cancer PC3 and skin melanoma SKMEL5 cell lines) to various small-molecule treatments (referred to as drugs for simplicity). It contains 6,100 treatment instances for 1,309 unique drugs, of which ca 650 are "Food and Drug Administration" (FDA) approved [1, 18] . To eliminate various biases in CMap (eg batch effect, microarray platforms), we filtered and normalized the raw CMap data set (downloaded from http://www.broadinstitute.org/cmap/) as described in detail previously [7] . For this study, we Table S3 ).
Disease associated microarrays
Microarray experiments on specific diseases were identified in the public microarray repository of NCBI GEO (http:// www.ncbi.nlm.nih.gov/geo/) [19] using disease medical subject heading (MeSH) terms that were attributed to each study [20] [21] [22] . In this study, we restricted our analysis to disease MeSH terms that are associated with at least one CMap drug. Moreover, we only analysed raw datasets conducted onHG-U133A and HG-U133-Plus2 microarray platforms to maximize comparability across resources. Next, all individual samples were manually annotated as "disease" or "healthy controls". In order to obtain reliable disease signatures, microarray samples (disease vs healthy) were retained only if derived from disease-relevant primary tissues. The RMA procedure was employed to normalize each dataset separately [23] .
In cases, where multiple studies were found for the same disease, we selected one representative per disease, such that distinction between disease and healthy samples is maximized based on inter-array Pearson's correlation (highest area under curve in receiver operating characteristic analysis), and discarded the others. Finally, in each disease-related gene expression profile, only probe sets present in HT_HG-U133A (HT Human Genome U133 Array Plate Set, 22277 probe sets) were kept and ranked according to their fold change. In total, we obtained here a total of 40 disease-associated gene expression profiles from 1,748 individual microarray samples (for details refer to Table S1 ).
Similarity score of drugs and diseases
To calculate profile similarity of a drug with a disease, we adapted a profile comparison method initially developed for drug-drug comparisons [7] . First, a disease-related signature was defined from the top and bottom 250 ranked probe sets of drug-associated gene expression profiles. We then computed disease-drug similarity by querying the up and down regulated signatures of the disease within drug-induced gene expression profiles (HT_HG-U133A, 22277 probe sets without 6 Present/Absent call filtering) using gene set enrichment analysis (GSEA, weighted) [24] . At last, two enrichments scores for up/down disease signatures were averaged to derive a final score for disease-drug similarity. We assessed whether known drug-disease associations (indications, excluding 'antidotes' from http://www.drugs.com/medical_conditions.html update Oct 7th, 2013) are significantly anti-correlated using a nonparametric Wilcoxon signed-rank test. To this end, similarity scores from each cell line were ranked in the range of [0, 1] and pooled together.
For each disease, we compared the similarity scores of known drug associations to all other drugs present in CMap ( Figure S1 and Table S2 ). Significantly anti-correlated diseases were defined as P-value < 0.05 after false discovery rate (FDR) correction for multiple testing.
Metastatic colon cancer gene signature
To identify novel therapeutics against metastatic CRC, we utilized a consensus gene signature defined by Jorissen et al. [25] . From two independent sets of colorectal cancers, a metastatic (Table S3 ). Probe sets not present in CMap dataset (HT_HG-U133A platform) were removed from the signature. After filtering, the metastasis signature was compared against the CMap reference collection that contains 4,849 gene expression profiles from three cell lines treated with 1,144 distinct drugs. We used the scoring approach described above to quantify profile similarity between drugs and the metastasis signature. For each drug, a final score was obtained by averaging the enrichment scores across all replicates from three cell lines (Table 7   S4 ). We further examined the top 20 drugs with lowest scores (anti-correlated) and manually searched in the literature whether these drugs were previously associated with colon cancer or metastasis.
Cell lines and reagents
The colorectal cancer cell lines HCT 116 and HT-29 were obtained from ATCC (Manassas, VA, USA) and maintained in DMEM (PAA, Piscataway, NJ, USA) + 10% FCS (PAA), 100 U/mL penicillin (PAA) and 100 μg/mL streptomycin (PAA) in a humidified atmosphere of 5% CO2 at 37°C. The cell lines were tested for authenticity by DSMZ (Braunschweig, Germany) on a regular basis. Enilconazole (Imazalil) and troglitazone were obtained from Sigma-Aldrich (St. Louis, MO, USA) and Neochema (Bodenheim, Germany), citalopram was obtained from Lundbeck (Hamburg, Germany).
MTT Proliferation Assay
The WST-1 reagent (Roche, Mannheim, Germany) is reduced by metabolically active cells to formazan, an insoluble purple dye which can be measured in a spectrophotometer, and was used according to the manufacturer's instructions. Cells were seeded in quadruplicates in increasing cell numbers in 96-well plates (125/well, 250/well, 500/well, 1000/well). After 12h adhesion time the cells were treated with the compounds as indicated. 120 h later 10 µl of WST-1 reagent were added to each well and the cells were again incubated for 4h at 37°C and 5% CO2. After incubation and 1 min shaking, the absorbance was measured on a Genios Microplate Reader (Tecan, Männedorf, Switzerland).
Clonogenic Survival Assay
Clonogenic survival assay was done as previously described [26, 27] . In brief, tumor cells were plated in triplicates to yield 50 to 100 colonies per culture flask, treated with the compounds in 
Migration Assay
The migration of tumor cells under treatment was measured via transwell assays as described previously [26, 27] . Briefly, cells were incubated with the compounds in various concentrations for 2 hours. Then 200 µl of cell suspension (3 × 105 cells/mL) were added in triplicate transwells (Matrigel-coated transwell inserts (8 μmol/L pore size; Becton Dickinson)). After 18 hours of incubation, migratory tumor cells had invaded the underside of the membrane, were fixed, stained in thiazine and eosine solution and sealed on slides. Quantification was done by microscopic counting.
TGF-β signaling assay
To demonstrate the effects of the three compounds on the TGF-β signalling pathway, we utilized a cell line stably expressing a secreted alkaline phosphatase (SEAP) reporter inducible by SMAD3/4-inducible elements (SBE), called HEK-Blue TGF-β sensor cell line (Invivogen, San Diego, CA, USA). This way, downstream activation of the TGF-β signalling pathway can be measured spectrophotometrically in the cell culture supernatants. The effects of the three compounds on TGF-β signaling pathway were analyzed using the HEK-Blue TGF-β kit (Invivogen, San Diego, CA, USA) according to the manufacturer's instructions.
Animal experiments
All animal experiments strictly adhered to local and federal regulations as well as FELASA guidelines, and were approved by the local authorities prior to initiation. 
Upon euthanasia, the livers and lungs of the animals were removed and immediately fixed in 4% PFA. After paraffin embedding, the FFPE tissue was cut in 10 µm (liver) or 2 µm (lung) sections using a Leica microtome (Wetzlar, Germany). Lungs were cut in a representative layer in the coronal plane; livers were cut in three representative layers (cranial third, middle third, caudal third) in the transversal plane to be able to detect the majority of metastatic lesions. The tissue sections were stained with a standard H/E protocol and metastases were counted.
Statistical analysis
Datasets were screened for outliers with the ROUT method (Q = 10%) [28] Annexin-positive cells were considered apoptotic and the ratio apoptotic cells / total cells was calculated.
RESULTS
Reverse profile searches for retrieval of drug-disease associations
To evaluate the general validity of the inverse signature approach, we assessed how well the known disease-drug indications were recapitulated by the expression-based inverse correlation of disease-drug relations for individual diseases. To this end, we first normalized the CMap dataset to obtain 4,849 drug-induced gene expression profiles from three main cell lines (HL60, MCF7 and PC3) treated with 1,144 distinct drugs [7] . In addition, we extracted diseaseassociated microarray experiments from publicly-available NCBI GEO microarray repository using Medical Subject Heading (MeSH) descriptors [19] . For this analysis, we next generated disease-associated gene expression profiles for 40 distinct diseases (details in Materials and Methods).
Indeed, in the normalized CMap data significant anti-correlations were found between drug and disease gene expression profiles for known drug-disease associations for seven out of 40 diseases ( Figure S1 ). Anti-correlations were most successful in the retrieval of disease-drug relations involving anti-cancer agents that were additionally linked to multiple cancers (six out of seven significant diseases), including colorectal cancer ( Figure S1 ). Based on this result, we focused on colorectal cancer to predict novel drug compounds aiming specifically at an inhibition of metastasis as the latter is of considerable clinical relevance.
Prediction of novel drug compounds for metastatic CRC
As CRC scored very prominently among the general disease-drug relations and because there are insufficient treatment options, particularly for inhibiting metastasis, we chose to illustrate the power of the inverse-signature method by predicting and validating drugs used in other indications as candidates for CRC treatment. Several gene expression signatures for CRC are available, but the most pressing need is for drugs that inhibit metastasis which could also be used as an adjuvant therapy. As opposed to previous studies that have used healthy versus [29] , we rather chose to compare non-metastatic tumors versus metastatic primary tumors and metastases, to define a gene signature of metastatic potential rather than a general cancer signature. Several groups have studied the gene expression differences between primary and metastatic colon cancers to explain the molecular basis of the metastatic process and predict clinical outcomes [25, [30] [31] [32] . In this study, we decided to employ the reproducible gene expression signature from [25] that emerged as a consensus from two independent comparisons of Dukes' stage D versus stage A colorectal cancers (Table S3, Table S4 ), were verteporfin [33] , resveratrol [34] and novobiocin [35] ; all of which have already been shown to inhibit migration and/or the metastatic development of cancer cells (Table 1 , [33] [34] [35] ). Upon drug treatment by any of these three drugs (Figure 2 ), fibronectin 1, collagen type V, notch homolog 3, platelet derived growth factor C, versican, integrin beta 5 and secreted phosphoprotein 1 are down-regulated. Four of the proteins encoded by these genes are involved in interactions between the extracellular matrix (ECM) and ECM-receptors ( Figure S2 ). The proteins fibronectin 1 and its receptor integrin beta 5 together are vital for cell migration [36] . This confirms the metastatic CRC gene signature to be appropriate for our purpose. The candidate drugs found by inverse profile search do not fully overlap in the set of genes whose expression is inverted relative to the disease profile. Thus, to find the most relevant drug candidates, we refined our list of plates independent of its PPARγ action [37, 39] and to inhibit pulmonary metastasis of osteosarcoma [38] . Second, citalopram, an antidepressant drug of the selective serotonin reuptake inhibitor (SSRI) class is approved to be used in humans but not an obvious candidate for screening against metastatic CRC. The third candidate enilconazole is a fungicide that has only been approved for topical use in veterinary medicine. Hence, the three candidates to be validated experimentally for their efficacy against metastatic CRC are not only chemically diverse, but come with different levels of expectation.
Mode of action
To better understand the underlying basis of our predictions, we set out to find the main mode of action of the three selected compounds. There are various signalling pathways that could play a role. One of them, transforming growth factor-beta (TGF-β) exerts its effects on cell proliferation, differentiation and migration in part through its modulation of extracellular matrix components, such as fibronectin and plasminogen activator inhibitor-1 (PAI-1) [40] which we find downregulated by the candidate drugs. It has recently been shown that resveratrol inhibits the TGF-β1-induced increase in cell adhesion, migration and invasion of A549 lung cancer cells [41] . Troglitazone has also been shown to have anti-migratory properties and II and with reduced TGF-β release [42] and to inhibit the TGF-β-induced epithelialmesenchymal transition of primary alveolar epithelial cells [43] . Based on similarity in downregulated genes (Figure 2) , in particular the strong inhibition of the fibronectin 1 gene and integrin beta 5, our expectation is that our other candidate drugs would also exert their antimigratory effect through inhibition of TGF-β signalling. To demonstrate the effects of the three compounds on the TGF-β signalling pathway, we utilized a cell line stably expressing a reporter (Figure 4 ). While we were specifically searching for anti-metastatic compounds, we additionally sought to avoid growth stimulatory effects on primary tumors. For this purpose, the three compounds were tested for effects on proliferation. They did in fact inhibit this process albeit to a different extent (Figure 4) .
Based on the promising results of the in vitro assays, next we tested the three compounds in a subcutaneous tumor model in mice ( Figure 5A ) [44] . We anticipated inhibition of tumor growth as all three compounds had demonstrated anti-proliferative effects. Immunodeficient mice (NOD scid gamma) were subcutaneously implanted with tumor fragments and monitored for tumor growth. All three compounds significantly inhibited the growth of subcutaneous tumors, but enilconazole and citalopram showed the most profound effects ( Figure 5A ). Of these two, In an orthotopic model, we demonstrated that citalopram had effects on both CTC numbers, the gold-standard surrogate marker for metastatic activity [45] as well as on the number of hepatic metastases, which is the clinically apparent outcome of a tumor's metastatic activity.
Due to low tolerability in the subcutaneous model, we could not test enilconazole and troglitazone in the orthotopic CRC model. Still, the in vitro experiments show the desired effect so that they represent promising leads to arrive at similar compounds, which are tolerated better and can be tested against metastatic CRC in the future.
Whereas the number of hepatic metastases was significantly reduced in the citalopram treated orthotopic CRC mice, the number of pulmonary foci was reduced as well, although this effect failed to reach statistical significance. This can most likely be explained by the filter effect of the hepatic capillary bed. As previously shown, the number of circulating tumor cells is significantly reduced in the blood after having passed the liver (i.e., the hepatic veins) as compared to before passing the liver (i.e., in the portal vein, [46] ). This filter effect may have weakened the impact of the treatment on pulmonary metastasis.
The heterogeneity of cancers and especially CRC makes us hypothesize that even better novel therapies could be developed through systems pharmacology. There are many different subtypes, both genetically, such as microsatellite-stable (MSS) versus unstable (MSI) or BRAFdriven versus KRAS-driven and histologically, such as serrated versus classical CRC [47] . In the future, the sub-classification and molecular characterization of these CRC subtypes into more specific diseases as well as the development of corresponding murine disease models that mimic the specific disease subtypes will allow for the discovery of better targeted, stratified therapies.
We conclude that our implementation of the reverse gene expression profiling concept shows very promising results for the retrieval of novel candidate drugs; in particular for the treatment of cancer-like disease as we have shown in our general analysis. Indeed, CMap employs cancer cell lines to establish drug-induced gene expression profiles where many genes involved in cancer-relevant pathways are expressed. In the LINCS consortium, more data are being generated for various types of human primary cells and cell lines that will even improve the power of this approach (http://www.lincsproject.org) . More relevant cell line or tissue models will make this approach more broadly applicable to other types of diseases in addition to cancer.
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